- Home
- CNTB vs FBIO Comparison
CNTB vs FBIO Comparison
Compare CNTB & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | FBIO |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 113.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTB | FBIO |
|---|---|---|
| Price | $2.80 | $3.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.50 | ★ $16.50 |
| AVG Volume (30 Days) | 152.2K | ★ 560.7K |
| Earning Date | 02-14-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $762,000.00 | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | $24,739.01 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $1.33 |
| 52 Week High | $3.28 | $4.20 |
Technical Indicators
Market Signals| Indicator | CNTB | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 67.40 |
| Support Level | $2.50 | $3.54 |
| Resistance Level | $2.89 | $3.81 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 86.63 | 82.32 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.